

biolitec AG: group revenue amounts to Euro 21.1 million in the first half of the fiscal year 2012/13

Sales increase of 1.8 million compared to last year period – Trade of shares of biolitec AG, Jena is terminated – biolitec Unternehmensbeteiligungs I AG, Wien operates again under biolitec AG

Wien/Jena, March 26, 2013 – biolitec AG (ISIN AT0000A0VCT2), Vienna, listed in the Entry Standard of the Frankfurt stock exchange, which merged with biolitec AG, Jena, on 15 March 2013, achieved a group revenue of Euro 21.1 million in the first half of the fiscal year 2012/2013. Thereby, the revenue was Euro 1.8 million above the same period in the previous year. The revenue growth of more than 9.1% is attributable to the growing demand for biolitec's mainstays of sales, e.g. the endoluminal laser treatment of veins (ELVeS-Radial™). With this method, the damaged vein is treated with laser light, and the vein is broken down by the body. The injection port for the fibre is the only entrance point needed, so that nearly no scars remain. In comparison to conventional therapies, e.g. stripping, the prevention of post-operative discomforts is one of the outstanding features of the ELVeS Radial™ laser therapy. New therapies such as the outstanding new development in gynaecology, the revolutionary laser system HOLA™ (Hysteroscopic Outpatient Laser Applications) for the treatment of myomas, or the laser therapy for haemorrhoids of higher grades, the so called Laser HaemorrhoidoPlasty (LHP™), receive positive responses from medicals and patients alike.

The gross profit amounted to Euro 15.0 million (previous year: Euro 12.0 million) and EBIT increased to Euro 1.4 million (previous year: Euro 0.92 million).

R&D expenditures for the first half of the fiscal year 2012/2013 of Euro 1.7 million (about 8% of sales) compared to the previous year (Euro 1.9 million) remain unchanged (in terms of percentage) on the required level to ensure the company's long term growth and profitability. Sales costs were increased to Euro 6.0 million (compared to Euro 5.5 million in the last year's period). Earnings per share were at Euro 0.10 in comparison to Euro 0.06 in the same period of the previous year.

Major revenues of biolitec AG, Jena resp. Vienna, were generated in Europe and North America. With Euro 7.3 million, sales in North America

Corporate News



biolitec AG

Otto-Schott-Str. 15

07745 Jena

www.biolitec.de

increased by +1% compared to previous year's level. European sales amounted to Euro 7.4 million (previous year: Euro 7.8 million). Our foreign subsidiaries, especially in the Arabian region and Asia, contribute increasingly to overall results and showed pleasingly high growth rates of +45% to Euro 6.4 million in comparison to the first half of the previous year. biolitec's medium-term goal to increase these markets' proportion of sales up to one third and thus lay the basis of further growth adapted to the world market situation could thus nearly be achieved in the first half of the fiscal year 2012/2013.

Sales in the business segment Meditec increased by +12% to Euro 20.7 million in the first half of the year; in the Pharma segment, the sales further amounted to modest Euro 0.14 million.

As already reported, the preparation of the annual financial statement 2011/2012 has been delayed longer than expected due to increased auditing work and the merger process. biolitec has decided to publish the first half of 2012/2013 even without available audit for the annual financial statement 2011/2012 in order to provide its shareholders with the fullest possible information about the company's situation.

In the meantime, the shares of biolitec AG (ISIN DE0005213409), Jena, listed in the Prime Standard of the Frankfurt stock exchange, are removed from trading due to the merger. The old shares of biolitec will be changed to the new value in the Entry Standard into shares of biolitec AG (ISIN AT0000A0VCT2) in the course of the merger. The trading of the new biolitec shares will be resumed immediately after expiry of the corresponding periods in the quality segment Entry Standard of the Frankfurt stock exchange.

About biolitec®:

biolitec® AG is one of the leading companies worldwide in the field of medical laser treatments and the only provider that possesses all relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial™ (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas® laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as ophthalmology also belong to the business field of biolitec®. biolitec® AG (ISIN AT0000A0VCT2) is listed in the Entry Standard. Further information at www.biolitec.de.

Investor Relations

Jörn Gleisner

Tel.: +49 (0) 3641/5195336

Fax: +49 (0) 3641/5195333

E-mail: joern.gleisner@biolitec.com